OBJECTIVE： To investigate and analyze the status quo of formulation of clinical guidelines in force for cancer treatment in China. METHODS： Retrieved from CBM， CNKI and Wanfang database， the literatures about clinical guidelines for cancer treatment were collected during database establishment and Sept. 2017. General characteristics of guideline were analyzed descriptively （general information， formulation institution， cancer type， formulation method， etc.）， and AGREEⅡ tool was used to evaluate the quality of evidence-based guideline. RESULTS & CONCLUSIONS： A total of 61 guidelines were included， involving 55 western medicine guidelines， 6 Chinese medicine guidelines； 42 guidelines were formulated by related industrial associations， 9 by National Health and Family Planning Committee （including 3 specifications）， 6 by related hospitals， 4 by other institutions. The publication time ranged 2002-2017. Guideline publication institutions included journals of Chinese Medical Association and related academic conferences. Top malignant cancer in the list of mortality were involved in China （such as liver cancer in 9 guidelines， gynecologic cancer and colon cancer in 7 guidelines， lymphoma/leukemia in 6 guidelines， lung cancer in 5 guidelines， breast cancer， pancreatic cancer and oral cancer in 4 guidelines）. The formulation methods included seminar and consensus， evidence-based formulation， literature review， Delphi and seminars， and reference to foreign literature. Among 61 guidelines， 14 guidelines were evidence-based guideline. Average scores of 6 evaluation items （scope and object， participants， rigorous formulation， clear expression， applicability， editorial independence） in 14 guidelines were 89％， 33％， 38％， 77％， 49％， 2％， the quality of which were not high. Formulation of clinical guideline of cancer treatment in China starts late and has a small number； there are large differences in the distribution of guidance types， slow development （only 9 guidelines were update edition）； most of the guidelines have not been updated； their qualities need to be improved. The current guidelines are not compatible with the huge demand and high risk of cancer burden in China. Therefore， it is urgent to develop high quality evidence-based clinical treatment guidelines for cancer and perfect evidence-based guidelines for clinical use of antitumor drugs.